Go to Page # Page of 16

Comparison of SurePath and GluCyte LBC Platforms.

 Reza Alaghehbandan MD
  10th-Dec-2018
Description: The objective is to assess and compare the predictability of novel biomarkers, MCM/Top2A HPV E6E7 mRNA and HPV DNA in women with ASC-US technology in SurePath and Glucyte Cell solution liquid-based cytology(LBC) platforms.
Important Tags: HPV DNA
Views: 2139
Domain: Medical
Category: Biology
Contributing Organization: ESP-Pathology
 ‐ More of their Presentations
weSRCH App on Apple
Contents:
Comparison of SurePath and GluCyte LBC
platforms in detecting CIN2+ among ASCUS cytology patients using biomarkers
Reza Alaghehbandan, MD, MSc, FRCPC, FCAP

Department of Pathology, Royal Columbian Hospital (RCH)
Faculty of Medicine, University of British Columbia (UBC)
Vancouver, BC, Canada

I declare no conflicts of interest.

• Two commercially available LBC systems, ThinPrep (Hologic In ... See more

Recent Presentations

...
15 February, 2019
Yuan Yuan MD PhD
14 February, 2019
...
13 February, 2019